PLA2G2A and breast cancer: We used our recently validated quantitative, convenient, highly reproducible PLA2 assay method [16] and showed for the first time that plasma PLA2 activities from patients with CRC, LC, PC, and bladder cancer (BC) were significantly higher than those of healthy controls.